No biomarker
No biomarker
|
Uterine Corpus Leiomyosarcoma
Uterine Corpus Leiomyosarcoma
|
pazopanib
Sensitive: A2 - Guideline
|
|
Uterine Corpus Leiomyosarcoma
Uterine Corpus Leiomyosarcoma
|
Aromatase inhibitor
Sensitive: A2 - Guideline
|
PGR positive
PGR positive
|
Uterine Corpus Leiomyosarcoma
Uterine Corpus Leiomyosarcoma
|
Aromatase inhibitor
Sensitive: A2 - Guideline
|
PGR positive
PGR positive
|
Uterine Corpus Leiomyosarcoma
Uterine Corpus Leiomyosarcoma
|
medroxyprogesterone
Sensitive: A2 - Guideline
|
|
Uterine Corpus Leiomyosarcoma
Uterine Corpus Leiomyosarcoma
|
medroxyprogesterone
Sensitive: A2 - Guideline
|
PGR positive
PGR positive
|
Uterine Corpus Leiomyosarcoma
Uterine Corpus Leiomyosarcoma
|
megestrol
Sensitive: A2 - Guideline
|
|
Uterine Corpus Leiomyosarcoma
Uterine Corpus Leiomyosarcoma
|
megestrol
Sensitive: A2 - Guideline
|
|
Uterine Corpus Leiomyosarcoma
Uterine Corpus Leiomyosarcoma
|
AZD5363
Sensitive: C3 – Early Trials
|
CD70 expression
CD70 expression
|
Uterine Corpus Leiomyosarcoma
Uterine Corpus Leiomyosarcoma
|
ARX305
Sensitive: C3 – Early Trials
|
FN1-ALK fusion
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
Uterine Corpus Leiomyosarcoma
|
lorlatinib
Sensitive: C4 – Case Studies
|
FN1-ALK fusion
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
Uterine Corpus Leiomyosarcoma
|
alectinib
Sensitive: C4 – Case Studies
|
FN1-ALK fusion
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
Uterine Corpus Leiomyosarcoma
|
crizotinib
Resistant: C4 – Case Studies
|
FN1-ALK fusion
FN1-ALK fusion
|
Uterine Corpus Leiomyosarcoma
Uterine Corpus Leiomyosarcoma
|
pazopanib
Resistant: C4 – Case Studies
|
